肿瘤学合作研究和许可协议（2021-2026）

本报告调查和分析了肿瘤学领域 2900 多项合作研究和授权协议，深入分析了全球商业性意义的伙伴关係的结构、条款、价值和趋势。

目录

执行摘要

第一章：引言

第二章：肿瘤学合约趋势

• 介绍
• 过去几年在肿瘤学领域的合作
• 肿瘤学合作：按合约类型划分
• 肿瘤学合作：按产业划分
• 肿瘤学合作：依发展阶段划分
• 肿瘤学合作：依技术类型划分
• 肿瘤协作：依疾病类型分類的治疗指征

第三章 肿瘤合作的财务协议条款

• 介绍
• 肿瘤学合作的财务条款已发表。
• 肿瘤学合作项目的主要金额
• 肿瘤合约预付款
• 肿瘤合约中的里程碑付款
• 肿瘤学领域的权利金费率

第四章：肿瘤学领域的主要合约和承包公司

• 介绍
• 在肿瘤学合作方面最积极主动的公司
• 肿瘤领域最活跃的承包公司名单
• 高薪肿瘤科合约

第五章：肿瘤学合约记录

• 介绍
• 可提供合约的肿瘤学合作项目

第六章：肿瘤治疗标靶合约

• 介绍
• 合约：透过肿瘤治疗标靶
• 合约记录
• 合约记录 - 肿瘤合约：按公司分类 (AZ)
• 合约记录 - 肿瘤合约：按技术类型分类
• 合约类型的定义
• 关于 Biopharma Research Ltd.
• Current Partnering
• Current Agreements
• 理想合作伙伴近期报告标题

Gain Strategic Advantage in the Most Competitive Therapeutic Space in Biopharma

This report offers the most comprehensive, up-to-date analysis of oncology dealmaking available today. Covering 2,900+ real-world deals, the report gives you unparalleled insight into the structure, terms, values, and trends behind the world's most commercially significant partnerships.

This fully revised edition includes financials, development-stage analysis, and contract access for oncology deals involving the industry's leading players-from early discovery through to commercialization.

Key Features & Benefits

• Covers 2,900+ Oncology Deals

Gain a detailed view of oncology deal structures, values, and strategic rationale across the most active sector in life sciences.

• Access Deal Financials and Milestone Data

Review headline values, upfronts, milestones, royalties, and stage-specific terms to benchmark your own transactions.

• Real-World Contracts for Deep-Dive Due Diligence

Where available, access SEC-filed contracts directly from the report to examine critical clauses and execution structures.

• Top Dealmakers Identified and Profiled

Spot the 25 most active companies in oncology partnering and understand how they approach collaboration and licensing.

• Targeted Search via Directories

Explore deals by company A-Z, therapeutic target, and technology type-with hyperlinks to full deal records and available contract documents.

What's Inside - Chapter Breakdown

Chapter 1: Introduction

Overview of the report's scope, objectives, and key terms used throughout.

Chapter 2: Trends in Oncology Dealmaking

A detailed look at oncology licensing and collaboration activity by year, deal type, stage of development, therapeutic focus, and partnering trends.

Chapter 3: Financial Terms by Stage of Development

Breakdown of financial terms for oncology deals across discovery, preclinical, clinical, and commercial stages-organized by headline value, upfronts, milestones, and royalty rates.

Chapter 4: Top 25 Most Active Oncology Dealmakers

Company-by-company profiles with deal counts and access to online deal records and SEC-filed contracts.

Chapter 5: Detailed Oncology Deal Analysis

Focused analysis of oncology deals with available contracts, highlighting licensing rights, payment structures, and development responsibilities.

Chapter 6: Directory by Therapeutic Target

Organized listing of oncology partnering deals based on the specific cancer indication or biological target.

Final Section: Comprehensive Deal Directory

Searchable deal directory organized by:

• Company A-Z
• Technology type
• Therapeutic focus
• Each entry links to the full Current Agreements record and-where available-the original contract document.
• Who Should Use This Report?
• Business Development & Licensing Professionals - Benchmark deal terms and identify ideal partners for your oncology assets.
• Legal & Contracts Teams - Review real contracts and deal structures to support negotiations and compliance.
• Corporate Strategy & C-Suite - Evaluate competitive positioning in the oncology landscape and inform investment or alliance strategies.
• Investors & Analysts - Understand how value is assigned across oncology pipeline assets from early-stage to market-ready.
• Why This Report Matters
• Oncology is the most competitive and capital-intensive therapeutic area in biopharma-and also the most collaborative. This report is your complete guide to understanding how oncology partnerships are structured, what rights are exchanged, and what financial terms are achievable.
• Whether you're in-licensing, out-licensing, evaluating an acquisition, or negotiating a co-development alliance, this report gives you the context, data, and real-world documentation to drive smarter dealmaking.
• Understand the landscape. Benchmark the terms. Secure the right deal. Order your copy of Oncology Collaboration and Licensing Deals in Pharmaceuticals and Biotechnology today.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in oncology dealmaking

• 2.1. Introduction
• 2.2. Oncology partnering over the years
• 2.3. Oncology partnering by deal type
• 2.4. Oncology partnering by industry sector
• 2.5. Oncology partnering by stage of development
• 2.6. Oncology partnering by technology type
• 2.7. Oncology partnering by therapeutic indication

Chapter 3 - Financial deal terms for oncology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for oncology partnering
• 3.3. Oncology partnering headline values
• 3.4. Oncology deal upfront payments
• 3.5. Oncology deal milestone payments
• 3.6. Oncology royalty rates

Chapter 4 - Leading oncology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in oncology partnering
• 4.3. List of most active dealmakers in oncology
• 4.4. Top oncology deals by value

Chapter 5 - Oncology contract document directory

• 5.1. Introduction
• 5.2. Oncology partnering deals where contract document available

Chapter 6 - Oncology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by oncology therapeutic target
• Deal directory
• Deal directory - Oncology deals by company A-Z
• Deal directory - Oncology deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Oncology partnering since 2021
• Figure 2: Oncology partnering by deal type since 2021
• Figure 3: Oncology partnering by industry sector since 2021
• Figure 4: Oncology partnering by stage of development since 2021
• Figure 5: Oncology partnering by technology type since 2021
• Figure 6: Oncology partnering by indication since 2021
• Figure 7: Oncology deals with a headline value
• Figure 8: Oncology deals with upfront payment values
• Figure 9: Oncology deals with milestone payment
• Figure 10: Oncology deals with royalty rates
• Figure 11: Active oncology dealmaking activity since 2021
• Figure 12: Top oncology deals by value since 2021